

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	08/786,937
				Filing Date	01/22/1997
				First Named Inventor	PHILIPPE BOUCHARD
				Art Unit	1649
				Examiner Name	Christina Borgeest
Sheet	1	of	1	Attorney Docket Number	098501-0235299

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		HUIRNE ET AL., "Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study," Hum. Reprod. , Epub (Abstract), Vol. 21 (No. 6), p. 1408-15, (March 14, 2006).		
		FELBERBAUM ET AL., "Ovarian Stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study," Hum. Reprod., (Abstract), Vol. 15 (No. 5), p. 1015-20, (May 2000).		
		ALBANO ET AL., "Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation," Fertil. Steril., (Abstract), Vol. 67 (No. 5), p. 917-22, (May 1997).		
		DUIJKERS ET AL., "Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers," Human Reproduction, European Society for Human Reproduction and Embryology, Vol. 13 (No. 9), p. 2392-2398, (1998).		
		NELSON ET AL., "Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)," Fertil. Steril., (Abstract), Vol. 63 (No. 5), p. 963-9, (May 1995).		
		RIVIER ET AL., "Gonadotropin releasing hormone antagonists: novel structures incorporating N omega-cyano modified guanidine moieties," Biochem. Biophys. Res. Commun., (Abstract), Vol. 176 (No. 1), p. 406-12, (April 15, 1991).		
		BARIL ET AL., "A new method for controlling the precise time of occurrence of the preovulatory gonadotropin surge in superovulated goats," Theriogenology, Vol. 45 (No. 3), p. 697-706, (February 1996).		
		DUBOURDIEU ET AL., "Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH," J. Clin. Endocrinol. Metab., (Abstract), Vol. 78 (No. 2), p. 343-7, (February 1994).		
		HAVIV ET AL., "In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone," J. Med. Chem., (Abstract), Vol. 37 (No. 5), p. 701-5, (March 4, 1994).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.